Characteristics of the patients in the analysis (N = 147)
| Characteristics of the patients . | Data . |
|---|---|
| Age, median (range), y | 64 (38-86) |
| Age >70 y | 51 (35) |
| Male/female, % | 51/49 |
| Median time from diagnosis to pomalidomide (range), y | 4.6 (0.7-15) |
| Median no. of prior treatments (range) | 3 (1-9) |
| 1-2 prior lines | 31 (21) |
| 3 prior lines | 49 (33) |
| >3 prior lines | 67 (46) |
| Prior ASCT | 78 (53) |
| Prior bortezomib | 143 (97) |
| Refractory to last bortezomib regimen | 104 (71) |
| Prior lenalidomide | 147 (100) |
| Prior thalidomide | 103 (70) |
| Refractory to last lenalidomide regimen | 135 (92) |
| Primary refractory | 9 (6) |
| Relapsed and refractory | 138 (94) |
| Last lenalidomide dose | |
| 5/10/15/25, mg | 9 (6)/27 (18)/16 (11)/95 (65) |
| Last regimen before Pd | |
| Bortezomib-containing | 71 (48) |
| Lenalidomide-containing | 62 (42.5) |
| Other (conventional chemo) | 21 (14) |
| Best response to last regimen, before progression ≥VGPR/PR/NR or PD, % | 18/30/52 |
| Response (≥PR) to last lenalidomide regimen | 82 (56) |
| Time from last lenalidomide dose to pomalidomide, mo | 6.7 |
| Time from last lenalidomide dose to pomalidomide ≥18 mo | 37 (25) |
| Duration of last lenalidomide-based regimen | 9.3 |
| Duration of last lenalidomide-based regimen ≥12 mo | 61 (42) |
| eGFR <60 mL/min | 50 (34) |
| Platelet counts <100 × 109/L | 35 (24) |
| Hemoglobin <10 g/dL | 69 (47) |
| LDH > ULN | 61 (41.5) |
| Calcium >10.5 g/dL | 21 (14) |
| ISS 1/2/3 | 21 (14)/67 (46)/59 (40) |
| t(4,14)* | 13 (21) |
| t(14,16)* | 5 (8) |
| del17p* | 11 (17.5) |
| amp/add1q21* | 20 (30.5) |
| High-risk cytogenetics*,† | 23 (36) |
| Characteristics of the patients . | Data . |
|---|---|
| Age, median (range), y | 64 (38-86) |
| Age >70 y | 51 (35) |
| Male/female, % | 51/49 |
| Median time from diagnosis to pomalidomide (range), y | 4.6 (0.7-15) |
| Median no. of prior treatments (range) | 3 (1-9) |
| 1-2 prior lines | 31 (21) |
| 3 prior lines | 49 (33) |
| >3 prior lines | 67 (46) |
| Prior ASCT | 78 (53) |
| Prior bortezomib | 143 (97) |
| Refractory to last bortezomib regimen | 104 (71) |
| Prior lenalidomide | 147 (100) |
| Prior thalidomide | 103 (70) |
| Refractory to last lenalidomide regimen | 135 (92) |
| Primary refractory | 9 (6) |
| Relapsed and refractory | 138 (94) |
| Last lenalidomide dose | |
| 5/10/15/25, mg | 9 (6)/27 (18)/16 (11)/95 (65) |
| Last regimen before Pd | |
| Bortezomib-containing | 71 (48) |
| Lenalidomide-containing | 62 (42.5) |
| Other (conventional chemo) | 21 (14) |
| Best response to last regimen, before progression ≥VGPR/PR/NR or PD, % | 18/30/52 |
| Response (≥PR) to last lenalidomide regimen | 82 (56) |
| Time from last lenalidomide dose to pomalidomide, mo | 6.7 |
| Time from last lenalidomide dose to pomalidomide ≥18 mo | 37 (25) |
| Duration of last lenalidomide-based regimen | 9.3 |
| Duration of last lenalidomide-based regimen ≥12 mo | 61 (42) |
| eGFR <60 mL/min | 50 (34) |
| Platelet counts <100 × 109/L | 35 (24) |
| Hemoglobin <10 g/dL | 69 (47) |
| LDH > ULN | 61 (41.5) |
| Calcium >10.5 g/dL | 21 (14) |
| ISS 1/2/3 | 21 (14)/67 (46)/59 (40) |
| t(4,14)* | 13 (21) |
| t(14,16)* | 5 (8) |
| del17p* | 11 (17.5) |
| amp/add1q21* | 20 (30.5) |
| High-risk cytogenetics*,† | 23 (36) |